Results 121 to 130 of about 6,101 (249)

Prognostic factors and treatment-effect modifiers in spinal muscular atrophy [PDF]

, 2021
Spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease characterized by loss of motor neurons and muscle atrophy. Untreated infants with Type 1 SMA do not achieve major motor milestones, and death from respiratory failure typically ...
Baranello, G, Daigl, M, Evans, R, Gorni, K, Hawkins, N, Kotzeva, A, Mahajan, A, Muntoni, F, Scott, DA, Servais, L   +9 more
core  

Effective local treatment of necrotizing fasciitis using a chlorine solution obtained by electrolysis [PDF]

Srpski Arhiv za Celokupno Lekarstvo
Introduction. Spinal muscular atrophy (SMA) and acute lymphoblastic leukemia (ALL) are rare diseases, with usual onset in childhood. To date, no cases have been reported where these conditions co-exist in one patient.
Kovačević Predrag T.
doaj   +1 more source

Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment [PDF]

, 2021
Maren Freigang, Claudia D. Wurster, Tim Hagenacker, Benjamin Stolte, Markus Weiler, Christoph Kamm, Olivia Schreiber‐Katz, Alma Osmanovic, Susanne Petri, Alexander B. Kowski, Thomas Meyer, Jan Christoph Koch, Isabell Cordts, Marcus Deschauer, Paul Lingor, Elisa Aust, Daniel Petzold, Albert C. Ludolph, Björn H. Falkenburger, Andreas Hermann, René Günther   +20 more
openalex   +1 more source

B.06 Safety and efficacy of nusinersen in infants/children with spinal muscular atrophy (SMA): part 1 of the phase 2 EMBRACE study [PDF]

, 2018
PB Shieh, Gyula Acsádi, Wolfgang Mueller‐Felber, T. B. B. Crawford, Randal Richardson, Niranjana Natarajan, Diana Castro, Sarah Gheuens, Ishir Bhan, Giulia Gambino, Peng Sun, Wildon Farwell, S. Reyna, Jiri Vajsar   +13 more
openalex   +1 more source

Nusinersen in type 0 spinal muscular atrophy: should we treat? [PDF]

, 2020
Eloisa Tiberi, Simonetta Costa, Marika Pane, Francesca Priolo, Roberto De Sanctis, Domenico M. Romeo, Francesco Danilo Tiziano, Giorgio Conti, Giovanni Vento, Eugenio Mercuri   +9 more
openalex   +1 more source

Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps [PDF]

, 2018
Teresa Gidaro, Laurent Servais
openalex   +1 more source

Administration of nusinersen via paramedian approach for spinal muscular atrophy [PDF]

, 2020
Hideyuki Iwayama, Norimitsu Wakao, Hirokazu Kurahashi, Norika Kubota, Ayako Hattori, Toshiyuki Kumagai, Akihisa Okumura   +6 more
openalex   +1 more source

Intrathecal Administration of Nusinersen Using the Ommaya Reservoir in an Adult with 5q-Related Spinal Muscular Atrophy Type 1 and Severe Spinal Deformity [PDF]

, 2021
Vasileios Papaliagkas, Nikolaos Foroglou, Petros Toulios, Maria Moschou, Maria Gavriilaki, Konstantinos Notas, Evangelia Chatzikyriakou, Georgia Zafeiridou, Marianthi Arnaoutoglou, Vasilios Κ. Kimiskidis   +9 more
openalex   +1 more source

Spinal muscular atrophy and acute lymphoblastic leukemia - is it just a coincidence? [PDF]

Srpski Arhiv za Celokupno Lekarstvo
Introduction. Spinal muscular atrophy (SMA) and acute lymphoblastic leukemia (ALL) are rare diseases, with usual onset in childhood. To date, no cases have been reported where these conditions co-exist in one patient.
Jovanović Kristina, Dimić Jovana, Brkušanin Miloš, Nikolić Dejan, Škorić Dejan   +4 more
doaj   +1 more source

Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy [PDF]

, 2018
Kevin A. Strauss, Vincent J. Carson, Karlla W. Brigatti, Millie Young, Donna L. Robinson, Christine Hendrickson, Michael D. Fox, Robert M. Reed, Erik G. Puffenberger, William G. Mackenzie, Freeman Miller   +10 more
openalex   +1 more source